health-tech

In this episode of Medsider Radio, we sat down with Joe Rafferty CEO of Vesteck, a developer of medical devices intended to treat patients diagnosed with aortic aneurysms.

Joe is a seasoned executive with a wealth of experience designing, building, and commercializing medical devices. In this conversation, Joe shares his storied journey in the medtech space, from his broad experiences within the cardiovascular arena to his current role leading Vesteck. Joe offers valuable insights on building a high-functioning in-house team, raising capital, and tips for ensuring your commercial launches are successful.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

In this episode of Medsider Radio, we sat down with Rob Ball CEO of Shoulder Innovations, a leading orthopedic device company recognized for developing one of the most robust and stable glenoid platforms in the industry.

Rob, a graduate of Kettering University with a deep-rooted passion for engineering, has dedicated over two decades of his professional life to medical device technologies. Rob has over 30 issued or pending patents and has been instrumental in the growth of several organizations, most notably Tornier, where he drove the company’s revenue from $40 million to an impressive $300 million within a handful of years. 

In this interview, Rob shares his unique journey from the automotive industry to the realm of orthopedics, emphasizing the importance of balancing technical problem-solving with commercial realities.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

In this episode of Medsider Radio, we sat down with Tim Blair, CEO of ICHOR, an early-stage company developing a novel approach to thrombectomy in the peripheral vascular system.

With a rich, 30+ year career in the medtech industry, Tim Bhas held diverse roles spanning sales, marketing, and strategy development, both in multinationals and startups. In 2009, Tim brought his strategic vision to NAMSA, shaping it into one of the world's first Medical Research Organizations (MROs). Currently, as CEO and co-founder, Tim is leading ICHOR on its quest to transform thrombectomy in the peripheral vascular system.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

In this episode of Medsider Radio, we sat down with Dave Kuraguntla, co-founder and CEO of Alio, developers of transformative solutions for kidney health, including a remote patient monitoring platform that provides non-invasive, highly accurate, and multi-metric patient data. 

Dave holds a degree from the West Virginia School of Osteopathic Medicine. While pursuing a surgical residency, he co-founded Alio. And in this interview, Dave shares his journey from aspiring surgeon to revolutionizing kidney health. He discusses common entrepreneurial challenges, such as killing risks early on, being diligent around clinical accuracy, and collaborating with FDA.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

In this episode of Medsider Radio, we sat down with Joe Landolina, co-founder and CEO of Cresilon, developers of a groundbreaking technology that's pushing the boundaries of what's possible in the field of trauma care.

Joe was introduced to chemical lab research at a young age, which kindled a lifelong interest in discovering responsive, nature-derived materials. Embarking on his journey as an entrepreneur and innovator at only 17, Joe invented the technology behind Vetigel, a major breakthrough in the trauma field.

In this interview, Joe reveals the development process behind Vetigel, an innovative product that stops severe bleeding with remarkable speed. Joe expounds on the unorthodox paths he took to build the company and the importance of a well-rounded team that’s able to balance creative and conservative strategies.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

In this episode of Medsider Radio, we sat down with Will Martin, CEO of IRRAS, a company revolutionizing the treatment of intracranial bleeding.

Will is an accomplished executive with over two decades of hands-on experience in the medtech arena, including roles at Boston Scientific, Access Closure, Hotspur Technologies, and Athromed. Will's expertise in sales and marketing leadership propelled him to become the CEO of IRRAS. His contributions to startups and established strategics have solidified his reputation as a proven leader in the medical device space.

In this interview, Will shares his insights on understanding user needs and cultivating strong internal relationships while maintaining robust quality management systems.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

In this episode of Medsider Radio, we sat down with Waqaas Al-Siddiq, CEO of Biotrocity, a cutting-edge remote patient monitoring company focusing on the cardiac landscape. 

Waqaas has a dual Bachelor’s degree in Computer Engineering and Economics, a Master’s in Computer Engineering from Rochester Institute of Technology, and a Master’s in Business Administration and a Doctorate in Business Administration from Henley Business School. With over 15 years of experience in the technology and healthcare sectors, Waqaas has a strong track record of developing innovative solutions for remote patient monitoring and connected health. As the CEO of Biotricity, he leads the company's mission to revolutionize remote patient monitoring by leveraging cutting-edge technology and data-driven insights.

In this interview, Waqaas discusses the crucial role that passion and work ethic play in driving healthtech success. He shares valuable insights into understanding the needs of your target market for effective product development, as well as fostering a culture of continuous learning and improvement within your organization.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

In this episode of Medsider Radio, we sat down with Carol Burns, CEO of Cagent Vascular, a medical device company focused on developing and commercializing an innovative angioplasty balloon called the Serenator.

Carol is a seasoned CEO and serial entrepreneur with a passion for cardiovascular devices. Her tireless energy and proven track record have enabled Carol to excel in all phases of medical device development, from early-stage proof of concept to eventual commercialization. Carol thrives in the fast-paced startup world, leveraging her industry relationships and clinical knowledge to identify technologies with the highest potential for success.

In this interview, Carol highlights the importance of establishing the right team to lay the proper foundation for your medtech startup. We further discuss how to prioritize essential product features and their clinical applications for future growth, as well as overcoming fundraising challenges through effective networking. She also highlights the importance of listening to study investigators and designing strategic clinical trials to generate valuable data and drive success.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

In this episode of Medsider Radio, we sat down with Steve Dimmer, CEO of CurvaFix, a medical device company focused on developing innovative solutions for orthopedic procedures.

 
Steve holds a Bachelor of Science in Electrical Engineering from San Diego State University and a Master’s in Business Administration from the University of Washington. He has over 30 years of experience building medtech companies, including multiple start-ups and stints at several large multinationals.

In this interview, Steve highlights the importance of mitigating risk and pitching to investors early in the development process. He also provides valuable advice on designing clinical trials that meet specific goals based on his own experiences at CurvaFix. 

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

In this episode of Medsider Radio, we sat down with Lloyd Mencinger, CEO of Aqua Medical, developers of a platform technology for vapor-based endoscopic ablation designed to treat type 2 diabetes with a 30-minute outpatient procedure. 

 
Lloyd is a high-energy CEO with decades of international experience in medical device sales, marketing, and business development. He has a strong track record of delivering results in both blue-chip and early-stage companies, including Boston Scientific, Edwards Lifesciences, and Baxter Healthcare. 

In this interview, Lloyd highlights the critical role of capital efficiency and rapid iteration in the early-stage development of medtech startups. He also discusses the importance of driving value for the company versus solely focusing on an acquisition. 

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's a link to the full interview with Lloyd if you'd rather read the summary instead.

In this episode of Medsider Radio, we sat down with Dr. Sam Mazin, CEO of RefleXion, a therapeutic oncology company with a novel technology that marries positron emission tomography (PET) and computed tomography (CT) with radiotherapy.

 
Sam received a Bachelor of Applied Science in Computer Engineering from the University of Waterloo, Canada, and holds a Ph.D. in Electrical Engineering from Stanford University. He co-founded RefleXion Medical in 2009 and is the inventor of the company’s core technology, which aims to improve treatment outcomes in patients with tumors in the lung or bone resulting from primary and metastatic cancer. 

In this interview, Sam shares why a startup medtech company should focus on retiring risk and pitching investors as early as possible. He also talks about the most important aspects every entrepreneur should consider when designing clinical trials to meet various goals.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's a link to the full interview with Sam if you'd rather read the summary instead.

In this episode of Medsider Radio, we sat down with Dr. Ohad Arazi, CEO of Clarius, a leading provider of high-definition wireless ultrasound systems. 

With his extensive experience in the technology industry, ranging from the Israeli military to industry leaders like McKesson, Telus, and Zebra Medical, Ohad's impact on Clarius' persistent growth is undeniable.

In this interview, Ohad shares the inspiring story of Clarius and its innovative handheld ultrasound device. From navigating regulatory hurdles to training audiences on new technology, Ohad explains how Clarius has achieved impressive growth year after year and shares valuable insights relevant to any medtech startup.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's a link to the full interview with Ohad if you'd rather read the summary instead.

In this episode of Medsider Radio, we sat down with Dr. Meesha Dogan, co-founder and CEO of Cardio Diagnostics.

Meesha is a well-respected leader in the epigenetic space. After completing her Ph.D. in biomedical engineering, she co-founded Cardio Diagnostics and co-invented its patent-pending cardiac technologies, which seek to improve the early detection, diagnosis, and prevention of heart disease through objective risk assessment testing. 

In this interview, Meesha shares how her company was founded on the grounds of compelling scientific research. She also talks about the different methods to improve the clinical adoption of a device and explains the possible benefits of going public. 

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's a link to the full interview with Meesha if you'd rather read the summary instead.

In this episode of Medsider Radio, we sat down with Osman Khawar CEO of Diality.

After obtaining an MD from the University of Glasgow and an MPH from Johns Hopkins, Osman Khawar went on to become a board-certified nephrologist with a passion for serving dialysis patients. As the CEO of Diality, he and his team are in the midst of creating a hemodialysis system that's versatile, mobile, intuitive, and cost-effective. 

In this interview, Osman discusses why early-stage technical risk reduction matters and how to navigate regulatory clearance through collaborative relationships. He also shares valuable tips on building and leading a mission-driven team.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's a link to the full interview with Osman if you'd rather read the summary instead.

In this episode of Medsider Radio, we sat down with Dan Zavorotny, co-founder of Nutrisense

Before co-founding Nutrisense, Dan worked as a healthcare management consultant at KPMG, where he advised Fortune 500 companies and three of the top five hospitals in the US. His company, Nutrisense, combines continuous glucose monitoring with personalized dietitian coaching to help people optimize their metabolic health based on real-time data. 

In this interview, Dan shares the pros and cons of running a DTC healthtech business, creative recruitment strategies, and the importance of early-stage customer feedback. 

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's a link to the full interview with Dan if you'd rather read the summary instead.

In this episode of Medsider Radio, we sat down with Mark Carbone, CEO of PN Medical.

Mark is the CEO of PN Medical, makers of medical devices that help improve pulmonary performance of patients, vocal artists, and professional athletes. Mark used his technology background and entrepreneurial experience to turn PN Medical into a frontrunner in the pulmonary space.

In this interview, Mark shares crucial lessons on how business leaders should build teams, bring a device to market, and protect the company’s brand.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's a link to the full interview with Mark if you'd rather read the summary instead.

In this episode of Medsider Radio, we sat down with Derek Herrera, founder and CEO of Bright Uro.

Derek served as an elite Marine officer in the U.S. military before suffering debilitating injuries while in the line of duty. Using his personal experience, he founded UroDev Medical, Habit Camera, and Bright Uro. His latest venture aims to launch an innovative urology device that’s meant to replace an invasive bladder diagnostic test that hasn’t changed in decades. 

In this interview, Derek shares important lessons in driving device innovation, running a medtech startup, and developing products efficiently.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Derek if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Torrey Smith, co-founder and CEO of Endiatx.

Torrey founded Endiatx alongside fellow Silicon Valley technology experts Dan Moyer, James Erd, and Alex Luebke. After leaving a different medical device company to scratch his entrepreneurial itch, Torrey and his co-founders are developing a new technology that aims to lower the barrier for patients to get diagnosed and treated for gastrointestinal diseases. 

In this interview, Torrey discusses the importance of both in-person and online networking, and best practices for sharing your product development progress with the investment community, stakeholders, and target patients. 

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Torrey if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Marc Zemel, CEO of Retia Medial.

Marc has extensive experience in fundraising for successful startups and is an experienced leader of Fortune 500 companies. Prior to founding Retia Medical, Marc earned an MS in Mechanical Engineering from MIT and an MBA in Sales and Marketing from Yale. He’s also held key leadership roles at Becton Dickinson as well as a capital equipment start-up.

In this interview, Marc talks about managing a medtech start-up that’s developing groundbreaking technology while pursuing fundraising that drives sustainable growth.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Marc if you'd rather read it instead.

In this episode of Medsider Radio, we sat down with Ziv Peremen, CEO of X-trodes.

After completing his PhD in neurocognitive science with a specializaton in understanding consciousness, Ziv Peremen has spent the past 12 years focused on the intersection of data and physiology. Together with Professor Yael Hanein, an expert in the field of human-machine interface learning and inventor of innovative sensor technology, they founded X-trodes.

In this interview, Ziv discusses his wireless wearable sleep diagnostic technology, commercializing a product before FDA clearance, and how to build the right company infrastructure from the start.

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with Ziv if you'd rather read it instead.